The Deadly Effects of Smoking and Secondhand Smoke

Sep.01.2022
The Deadly Effects of Smoking and Secondhand Smoke
Smoking is a leading cause of death in the US, causing chronic obstructive pulmonary disease, asthma and even diabetes. Secondhand smoke is also harmful.

If you smoke, your body will be harmed - we all know that. But did you know that being around people who smoke today can also harm your body?


Smoking is the leading cause of death in the United States. However, it is often attributed to something else medically speaking. Deaths may be attributed to chronic obstructive pulmonary disease, asthma, and even diabetes - conditions that are worsened by smoking or caused by smoking.


If you don't smoke, you are already doing the first thing you can do to prevent these terrible, but preventable diseases. The second thing you can do is to avoid second-hand smoke," said Todd Mahr, an allergist and immunologist as well as an expert on the harmful effects of smoking at the Gunderson Health System. It means that if you are exposed to second-hand smoke, you are constantly in the presence of people who are smoking.


Second-hand smoke is a bigger problem for young children. When discussing third-hand smoke with parents, they often say "I never smoke around them," but the smoke still lingers on their clothing and in the surrounding area, which can still be harmful, according to Mahr. However, there is now one thing you can do to extend your life expectancy.


He said, "Some people don't consider e-cigarettes as smoking. Being unique is important, but being unique doesn't always mean it's a good thing. People say, 'I'm vaping. All I'm inhaling is water vapor.' But in reality, they contain chemicals that can lead to cancer.


This story is part of a series by the Valley Media Group exploring the leading causes of death from 1999 to 2020. The data in this story is sourced from the Centers for Disease Control and Prevention.


The fourth leading cause of death in the area.


Chronic Lower Respiratory Disease (CLRD) encompasses Chronic Obstructive Pulmonary Disease (COPD), including emphysema and chronic bronchitis, as well as asthma, pulmonary hypertension, and occupational lung diseases.


According to data from the Centers for Disease Control and Prevention, it is the sixth leading cause of death in the United States, responsible for 152,657 deaths.


In the valley region, 4,116 people died from CLRD in 2020, making it the fourth leading cause of death in La Crosse County, Vernon County, Dunn County, Trempealeau County, Chippewa County, and Monroe County in Wisconsin, as well as Houston County and Winona County in Minnesota.


Chronic obstructive pulmonary disease (COPD) accounts for the majority of chronic lower respiratory diseases and is primarily caused by smoking in approximately 85% of cases.


Over time, exposure to irritants in cigarette smoke can weaken the lungs' ability to resist infection, leading to tracheal inflammation and damage to air sacs or alveoli. Long-term exposure to air pollution, smoke, chemicals, or secondhand smoke also contributes to the development of chronic obstructive pulmonary disease (COPD), as does vaping e-cigarettes and smoking marijuana. Symptoms of COPD include shortness of breath, wheezing, or chronic coughing.


Chronic obstructive pulmonary disease (COPD) has decreased from being the fourth leading cause of death in the United States in 2018 to the sixth in 2020, but its incidence rate may be higher than expected.


More than 50% of adults with poor lung function are unaware that they have chronic obstructive pulmonary disease, according to a study conducted in 2013.


Dr. Hafiz Fakih, a pulmonary and critical care specialist at the Greater Los Angeles VA Healthcare System, explains that there may be a potential underreporting of deaths related to chronic obstructive pulmonary disease (COPD) due to the condition being listed as the cause of death instead of the actual underlying cause of death.


Fatal consequences


Smoking is terrible. But just how terrible is it?


Mahr states, "The most important thing is that smoking can lead to everything. We are talking about lower respiratory tract diseases, but it can lead to many illnesses and disabilities, actually harming every organ in the body.


Most Americans are aware that smoking has a significant impact on the lungs, but that's not all. According to Mahr, it affects a person's entire body.


Around 16 million Americans suffer from smoking-related diseases, including lung cancer and chronic obstructive pulmonary disease. However, smoking can also lead to or worsen heart disease, stroke, other lung diseases, diabetes, emphysema, and chronic bronchitis. It even increases the risks of tuberculosis and eye diseases and can severely damage our immune systems. From a medical standpoint, smoking can affect everything. In relation to the COVID-19 virus, smoking also increases the risk of infection.


In recent years, there has been a significant decrease in the smoking rates of adults, going from 20.9% in 2005 to 12.5% in 2020. Additionally, smoking rates among youth have dropped from 23% in 2000 to 2.3% in 2021.


According to Fakih, while the mortality rate for men suffering from chronic obstructive pulmonary disease (COPD) has decreased slightly, "the mortality rate for women with COPD is slightly higher," as the rate of female smokers declining is slower than that of men.


Race is also a factor in smoking rates - 21.9% of American Indians and Alaskan Natives smoke, as do 16.8% of African Americans and Blacks. Non-Hispanic white smokers have a slightly lower smoking rate at 16.6%, but their use of menthol cigarettes is only one-third that of African American smokers. Menthol products make smoking more enjoyable and harder to quit.


According to Fakih, we can manage the damage caused by smoking, but we cannot reverse it. When you quit smoking, the harm will come to an end.


The COVID-19 pandemic has heightened people's awareness of lung diseases. According to Mahr, it is now evident that simply wearing a mask every day is not the straightforward solution for calming lung infections and chronic illnesses.


It all depends on your personal risk factors. Respiratory illnesses are not very common, and most people would attribute them to community-acquired pneumonia and bronchitis. However, they are still fatal. Look at the statistics. Many people are struggling for their lives," Mahr said. "We know that one thing that increases your risk of disease and death is smoking. People should be aware of this. If possible, quit.


Disclaimer: 1. The content of this article is compiled from third-party information and is intended for industry exchange and learning purposes only. 2. The views expressed in this article do not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the content of the article. The compilation of this article is only for industry exchange and research purposes. 3. Due to limited compiling skills, the compiled article may not fully express the original article, please refer to the original article for accuracy. 4. 2FIRSTS fully supports the Chinese government on any statements and positions related to domestic, Hong Kong, Macau, Taiwan, and foreign affairs. 5. The copyright of the compiled information belongs to the original media and author, and if there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

2Firsts Hosts U.S. Compliance Briefing on Building PMTA Support Capabilities Across the Nicotine Supply Chain
2Firsts Hosts U.S. Compliance Briefing on Building PMTA Support Capabilities Across the Nicotine Supply Chain
2Firsts held a U.S. compliance briefing in Shenzhen to help vaping, heated tobacco and nicotine pouch supply chain companies strengthen PMTA support capabilities. The event focused on supplier documentation, quality systems, traceability, TPMF/TPMP pathways, age verification and customer audit readiness as U.S. compliance expectations increasingly extend deeper into the nicotine supply chain.
Events
Jun.12
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
From myblu to Zone: Imperial Brands Refocuses NGP Strategy in HY26
mperial Brands’ HY26 results point to a more selective NGP transition. The company is using cash flow from traditional tobacco to fund targeted investments in modern oral nicotine, heated tobacco and reusable vaping systems. Its decision to exit the legacy myblu vaping business in the U.S., while expanding Zone nicotine pouches. In Europe, Imperial’s NGP growth is being driven by a multi-category portfolio including blu, Pulze and Zone/Skruf.
Special Report
May.12
UK Disposable Vape Ban Marks One Year as Adult Use Falls to 8% and Youth Use to 13%
UK Disposable Vape Ban Marks One Year as Adult Use Falls to 8% and Youth Use to 13%
One year after the UK ban on single-use disposable vapes took effect, YouGov data commissioned by Action on Smoking and Health shows that 13% of 11-17-year-old vapers and 8% of adult vapers now mainly use disposable products.
Jun.18
AIR Romania Manufacturing Facility Expected to Begin Operations in Q1 2027
AIR Romania Manufacturing Facility Expected to Begin Operations in Q1 2027
AIR Limited announced on May 7, 2026, that it plans to open a new manufacturing facility of approximately 70,000 square feet in Stefanesti, Bucharest North, Romania. The facility is expected to begin operations by the first quarter of 2027. AIR said that once fully operational, the facility is expected to support more than 150 jobs and be capable of producing more than 4,000 tons of flavored shisha molasses each year.
May.08 by 2FIRSTS.ai
 Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
Philip Morris Lowers Profit Outlook as Zyn Faces Competition and FDA Delays
According to Reuters, Philip Morris International (PMI) lowered its 2026 adjusted earnings-per-share forecast amid regulatory uncertainty around Zyn nicotine pouches, rising competition and shipment pressure in the U.S. market.
PMI
Jun.02
ZYN by IQOS to Roll Out Across Tokyo From May 11 Through IQOS Shops and Lawson
ZYN by IQOS to Roll Out Across Tokyo From May 11 Through IQOS Shops and Lawson
Philip Morris Japan announced on April 23 at a product briefing that ZYN by IQOS, an oral tobacco pouch previously launched in selected areas, will expand sales in Tokyo. The company said the product will be released progressively from May 11 through IQOS shops, Lawson and other outlets in the city. The launch will include four flavors, each offered in Low and Medium intensity levels, for a total of eight products.
Apr.27 by 2FIRSTS.ai